Tag: global blood therapeutics
January 30, 2019
GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease
Global Blood Therapeutics (NASDAQ:GBT) today announced that data from its Phase 1/2 study of voxelotor in patients with sickle cell... December 7, 2018
Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering
Global Blood Therapeutics (Nasdaq:GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to... December 3, 2018
GBT Announces Positive 24-week Results from Phase 3 HOPE Study
Global Blood Therapeutics (Nasdaq:GBT) today announced updated efficacy and safety results from Part A of its Phase 3 HOPE Study... August 23, 2018
GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis
Global Blood Therapeutics (NASDAQ:GBT) announced today that it has entered into an exclusive worldwide licensing agreement with F. Hoffmann-La Roche... June 27, 2018